ImmuCell Corporation (NASDAQ:ICCC) Short Interest Up 147.1% in December

ImmuCell Corporation (NASDAQ:ICCC) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 15,418 shares, an increase of 147.1% from the November 30th total of 6,239 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 18,731 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily trading volume, of 18,731 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.2% of the company’s shares are sold short.

Hedge Funds Weigh In On ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Steadtrust LLC bought a new stake in ImmuCell Corporation (NASDAQ:ICCC) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 31,700 shares of the biotechnology company’s stock, valued at approximately $198,000. Steadtrust LLC owned about 0.35% of ImmuCell as of its most recent filing with the Securities and Exchange Commission. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

ImmuCell Trading Up 5.5%

ICCC stock traded up $0.32 during midday trading on Friday, hitting $6.12. 336,206 shares of the company’s stock were exchanged, compared to its average volume of 14,761. ImmuCell has a 1-year low of $4.28 and a 1-year high of $7.60. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $55.36 million, a PE ratio of 23.54 and a beta of 0.20. The business has a 50-day simple moving average of $5.69 and a two-hundred day simple moving average of $6.14.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. The business had revenue of $5.51 million for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of ImmuCell in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.